Refine
Year of publication
Document Type
- Preprint (789)
- Article (624)
- Book (2)
- Conference Proceeding (1)
- Working Paper (1)
Has Fulltext
- yes (1417)
Is part of the Bibliography
- no (1417)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (14)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- Jets (6)
- ALICE experiment (4)
- COVID-19 (4)
- Collective Flow (4)
- Heavy Ions (4)
- Heavy Quark Production (4)
- QCD (4)
- Quark-Gluon Plasma (4)
- prostate cancer (4)
- Branching fraction (3)
- Jets and Jet Substructure (3)
- SARS-CoV-2 (3)
- e +-e − Experiments (3)
- pp collisions (3)
- radical prostatectomy (3)
- ACLF (2)
- ALICE (2)
- Beauty production (2)
- Biodiversity (2)
- Charm physics (2)
- Corona (2)
- EGFR (2)
- Epileptischer Anfall (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Fasting (2)
- Glioblastoma (2)
- Glucose (2)
- Heavy-ion collisions (2)
- Immunology (2)
- Ketogenic diet (2)
- Leptin (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Liver diseases (2)
- Liver transplantation (2)
- Monte Carlo (2)
- Nephrons (2)
- Pandemic (2)
- Pandemie (2)
- Particle Correlations and Fluctuations (2)
- Particle and Resonance Production (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Pre-analytics (2)
- Quark Gluon Plasma (2)
- Quarkonium (2)
- Radiation (2)
- SARS-CoV‑2 (2)
- Seizure (2)
- Single electrons (2)
- Status epilepticus (2)
- Systematic Uncertainty (2)
- Time Projection Chamber (2)
- acute myeloid leukemia (2)
- acute-on-chronic liver failure (2)
- gene therapy (2)
- portal hypertension (2)
- transient elastography (2)
- 2-deoxyglucose (2-DG) (1)
- ALICE LHC (1)
- ALICE detector (1)
- APRI (1)
- ASAP (1)
- ATP (1)
- Advanced stage (1)
- Allergic asthma (1)
- Alpha-synuclein (1)
- Amino acid analysis (1)
- Analysis and statistical methods (1)
- Anti-kaon–nucleon physics (1)
- Anti-nuclei (1)
- Awareness campaign (1)
- BCOR (1)
- BCORL1 (1)
- BESIII (1)
- Balance function (1)
- Blood (1)
- Blood sample handling (1)
- Bodensee (1)
- Bodensee-Gebiet (1)
- Boosted Jets (1)
- Brain tumor (1)
- Branching fractions (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COVID‐19 (1)
- Caco-2 cells (1)
- Calorimeters (1)
- Cancer (1)
- Cancer check up (1)
- Cancer models (1)
- Cancer treatment (1)
- Cell motility (1)
- Central Bank Communication (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge correlations (1)
- Charged-particle density (1)
- Cirrhosis (1)
- Clinical Trials and Observations (1)
- Clinical presentation (1)
- Collective Flow, (1)
- Colorectal cancer (1)
- Comparative analysis (1)
- Comparison with QCD (1)
- Complex II (1)
- Complicated stage (1)
- Computed axial tomography (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Congenital ocular motor apraxia (1)
- Conservation biology (1)
- Cytoskeletal proteins (1)
- DNA sequence analysis (1)
- DTHR (1)
- Data management (1)
- Data processing methods (1)
- Death rates (1)
- Deep neural network (1)
- Developmental biology (1)
- Devic disease (1)
- Devic syndrome (1)
- Diabetes (1)
- Diabetes mellitus (1)
- D’Amico classification (1)
- EBV (1)
- EWSR1 (1)
- Ecosystems (1)
- Electron-pion identification (1)
- Electroweak Interaction (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Embryos (1)
- Endocannabinoids (1)
- Environment (1)
- Environmental impact (1)
- Everolimus (1)
- Evidence-based guidelines (1)
- FIB-4 (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- First-line regimen (1)
- Flohkrebse (1)
- Forschung (1)
- GABARAP (1)
- Gene expression (1)
- Gene fusion (1)
- Genetic engineering (1)
- Genetics (1)
- Genome-wide association studies (1)
- Gleason Score (1)
- Gleason score (1)
- Gradient boosting (1)
- HBT (1)
- HBV (1)
- HIV (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion detectors (1)
- Hepatitis C virus (1)
- Hepatocellular carcinoma (1)
- Hif-1 alpha (1)
- Hispanic people (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- Hyperammonemic encephalopathy (1)
- Hyperons (1)
- Hypertension (1)
- IHC (1)
- Imidacloprid (1)
- Immune suppression (1)
- Immunohistochemistry techniques (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Invertebrates (1)
- Ionisation energy loss (1)
- Isothermal Titration Calorimetry (1)
- Jet Physics (1)
- Jet Substructure (1)
- Joubert syndrome (1)
- K3EDTA plasma sampling (1)
- KRAS (1)
- Kaonic nuclei (1)
- Kd determination (1)
- Kidney transplantation (1)
- Konstanz (1)
- LABAs (1)
- LC3 (1)
- LEOSS (1)
- LIR motifs (1)
- LTER (1)
- Landkreis Konstanz (1)
- Large Hadron Collider (1)
- Large detector systems for particle and astroparticle physics (1)
- Lehre (1)
- Leukaemia (1)
- Lipidomics (1)
- Long‐term ecosystem research (1)
- Low energy QCD (1)
- MN1 (1)
- MR-spectroscopy (1)
- Machine learning (1)
- Material budget (1)
- Metabolomics (1)
- Metastasis (1)
- Metastatic tumors (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molar tooth sign (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-syndrome classification (1)
- Multi-wire proportional drift chamber (1)
- Multiple stressors (1)
- Muscheln (1)
- Mutation databases (1)
- Myeloid Neoplasia (1)
- NETs (1)
- NMO-IgG (1)
- NMR spectroscopy (1)
- NSCLC (1)
- Nanoplastics (1)
- Natural Language Processing (1)
- Neonatal urea cycle disorders (1)
- Neural Network (1)
- Neural network (1)
- Neurodegenerative syndromes (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Neutrophils (1)
- Nuclear modification factor (1)
- Nucleus (1)
- ORL (1)
- Observation (1)
- Oncology (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- PATZ1 (1)
- PSA (1)
- PSA screening (1)
- PSA-Screening (1)
- PTDM (1)
- PTEN (1)
- Paediatrics (1)
- Parkinson’s disease (1)
- Partial wave analysis (1)
- Pb–Pb (1)
- Pediatric (1)
- Performance of High Energy Physics Detectors (1)
- Plasma (1)
- Post-transplant (1)
- Predictive model (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate cancer (1)
- Proton (1)
- Proton–proton (1)
- Prävention (1)
- Psoriasis vulgaris (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RAS (1)
- ROS/RNS (1)
- Radiation exposure (1)
- Radical nephrectomy (1)
- Random forest (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Renal cancer (1)
- Renal system (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SPSS (1)
- SW480 cells (1)
- Sampling protocol (1)
- See (1)
- Semi-leptonic decays (1)
- Serum (1)
- Single muons (1)
- Site networks (1)
- Socio-ecology (1)
- Specialist training (1)
- Stem-cell therapies (1)
- Strangeness (1)
- Support vector machine (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- TOR inhibitor (1)
- TR (1)
- TUR-P (1)
- Teaching (1)
- Thermal desorption GC–MS (1)
- Tierökologie (1)
- Tracking (1)
- Transcriptome analysis (1)
- Transfer Learning (1)
- Transition radiation detector (1)
- Transurethral resection of the prostate (1)
- Transverse Momentum (1)
- Treatment (1)
- Treatment modification (1)
- Trigger (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGFR (1)
- Vector Boson Production (1)
- Viral infection (1)
- Vorsorgeuntersuchung (1)
- Warburg effect (1)
- Weiterbildung (1)
- Wide rapidity coverage (1)
- Word Embedding (1)
- Xenon-based gas mixture (1)
- accessory proteins (1)
- acoustic radiation force impulse (1)
- acoustic radiation force impulse imaging (1)
- acute chronic inflammation (1)
- acute decompensation (1)
- adipogenesis (1)
- adjuvant chemotherapy (1)
- advanced melanoma (1)
- amino acids (1)
- amphiregulin (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- aortic stenosis (1)
- aquaporin-4 (AQP4) antibody (1)
- arthritis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- atypical EGFR mutations (1)
- autophagy (1)
- bronchial allergen challenge (1)
- cART (1)
- cardiac remodeling (1)
- cell-free protein synthesis (1)
- cerebrospinal fluid (1)
- chromosomal integration (1)
- chronic hepatitis C (1)
- cirrhosis (1)
- clinical features (1)
- clinically important restrictions and symptoms (1)
- complete response (1)
- computed tomography (1)
- concordance (1)
- correlation (1)
- cytarabine dose (1)
- dE/dx (1)
- data management (1)
- data quality (1)
- deferred treatment (1)
- delayed treatment (1)
- desensitization (1)
- detector (1)
- diet (1)
- diffusion-weighted magnetic resonance imaging (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- downgrading (1)
- elderly (1)
- electroencephalography (EEG) (1)
- electronic diaries (1)
- endocrine-disrupting chemicals (1)
- epidemiology (1)
- epiregulin (1)
- experimental results (1)
- fasting (1)
- fibrotest (1)
- fusion biopsy (1)
- gastrointestinal stromal tumours (1)
- gene vectors (1)
- glioblastoma (1)
- glycolysis (1)
- haemophilia treatment (1)
- health-relatedquality of life (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic stem cells (1)
- hepatic encephalopathy (1)
- histological outcomes (1)
- immunohistochemistry (1)
- immunologic (1)
- inhaled steroids (1)
- interstitial lung disease (1)
- intrinsically disordered region (1)
- inverse stage migration (1)
- isocaloric ketogenic diet (1)
- ketogenic (1)
- ketone body (1)
- liver (1)
- liver cirrhosis (1)
- logistic models (1)
- long-acting β2-agonists (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- lung squamous cell carcinoma (LUSC) (1)
- machine learning (1)
- magnetic resonance imaging (1)
- mechanical ventilation (1)
- metabolic cancer therapy (1)
- metabolic disruptors (1)
- multicenter study (1)
- multiplexed immunofluorescence (1)
- myositis (1)
- neoadjuvant chemoradiotherapy (1)
- neurological manifestations (1)
- non-invasive fibrosis assessment (1)
- non-small-cell lung cancer (1)
- non-target chemical analysis (1)
- nonstructural proteins (1)
- nonviral gene delivery (1)
- obesogens (1)
- observational study (1)
- oral cavity cancer (1)
- point shear wave elastography (1)
- pollen allergy (1)
- portosystemic shunt (1)
- ppK − (1)
- predictive biomarker (1)
- predictive biomarkers (1)
- preschool asthma (1)
- prognosis (1)
- prostate neoplasm (1)
- prostate-specific antigen (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- radical prostatecomy (1)
- rare disease (1)
- rats (1)
- recurrent optic neuritis (1)
- respiratory failure (1)
- review (1)
- risk factors (1)
- risk stratification (1)
- second-line immunotherapy (1)
- severe uncontrolled asthma (1)
- spectra (1)
- spontaneous portosystemic shunt (1)
- stage II/III colorectal cancer (1)
- structural proteins (1)
- survival (1)
- systematic biopsy (1)
- targeted therapy (1)
- tiotropium (1)
- tolerance (1)
- transposition (1)
- treatment centres (1)
- tumor weight (1)
- tyrosine kinase inhibitors (1)
- upgrading (1)
- waiting time (1)
- Öffentlichkeit (1)
- Λ+c baryon (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1308)
- Frankfurt Institute for Advanced Studies (FIAS) (1057)
- Informatik (1022)
- Medizin (72)
- Geowissenschaften (11)
- Biowissenschaften (5)
- Institut für Ökologie, Evolution und Diversität (4)
- Biochemie, Chemie und Pharmazie (3)
- Informatik und Mathematik (3)
- Geowissenschaften / Geographie (2)
The ALICE Collaboration reports the measurement of the relative J/ψ yield as a function of charged particle pseudorapidity density dNch/dη in pp collisions at √s=7 TeV at the LHC. J/ψ particles are detected for pt>0, in the rapidity interval |y|<0.9 via decay into e+e−, and in the interval 2.5<y<4.0 via decay into μ+μ− pairs. An approximately linear increase of the J/ψ yields normalized to their event average (dNJ/ψ/dy)/〈dNJ/ψ/dy〉 with (dNch/dη)/〈dNch/dη〉 is observed in both rapidity ranges, where dNch/dη is measured within |η|<1 and pt>0. In the highest multiplicity interval with 〈dNch/dη(bin)〉=24.1, corresponding to four times the minimum bias multiplicity density, an enhancement relative to the minimum bias J/ψ yield by a factor of about 5 at 2.5<y<4 (8 at |y|<0.9) is observed.
he first measurements of the invariant differential cross sections of inclusive π0 and η meson production at mid-rapidity in proton–proton collisions at s=0.9 TeV and s=7 TeV are reported. The π0 measurement covers the ranges 0.4<pT<7 GeV/c and 0.3<pT<25 GeV/c for these two energies, respectively. The production of η mesons was measured at s=√7 TeV in the range 0.4<pT<15 GeV/c. Next-to-Leading Order perturbative QCD calculations, which are consistent with the π0 spectrum at s=0.9 TeV, overestimate those of π0 and η mesons at s=√7 TeV, but agree with the measured η/π0 ratio at s=√7 TeV.
The first measurement of two-pion Bose–Einstein correlations in central Pb–Pb collisions at √sNN=2.76 TeV at the Large Hadron Collider is presented. We observe a growing trend with energy now not only for the longitudinal and the outward but also for the sideward pion source radius. The pion homogeneity volume and the decoupling time are significantly larger than those measured at RHIC.
Harmonic decomposition of two particle angular correlations in Pb–Pb collisions at √sNN=2.76 TeV
(2012)
Angular correlations between unidentified charged trigger (t) and associated (a) particles are measured by the ALICE experiment in Pb–Pb collisions at √sNN=2.76 TeV for transverse momenta 0.25<pTt,a<15 GeV/c, where pTt>pTa. The shapes of the pair correlation distributions are studied in a variety of collision centrality classes between 0 and 50% of the total hadronic cross section for particles in the pseudorapidity interval |η|<1.0. Distributions in relative azimuth Δϕ≡ϕt−ϕa are analyzed for |Δη|≡|ηt−ηa|>0.8, and are referred to as “long-range correlations”. Fourier components VnΔ≡〈cos(nΔϕ)〉 are extracted from the long-range azimuthal correlation functions. If particle pairs are correlated to one another through their individual correlation to a common symmetry plane, then the pair anisotropy VnΔ(pTt,pTa) is fully described in terms of single-particle anisotropies vn(pT) as VnΔ(pTt,pTa)=vn(pTt)vn(pTa). This expectation is tested for 1⩽n⩽5 by applying a global fit of all VnΔ(pTt,pTa) to obtain the best values vn{GF}(pT). It is found that for 2⩽n⩽5, the fit agrees well with data up to pTa∼3–4 GeV/c, with a trend of increasing deviation as pTt and pTa are increased or as collisions become more peripheral. This suggests that no pair correlation harmonic can be described over the full 0.25<pT<15 GeV/c range using a single vn(pT) curve; such a description is however approximately possible for 2⩽n⩽5 when pTa<4 GeV/c. For the n=1 harmonic, however, a single v1(pT) curve is not obtained even within the reduced range pTa<4 GeV/c.
The ALICE Collaboration has measured inclusive J/ψ production in pp collisions at a center-of-mass energy √s=2.76 TeV at the LHC. The results presented in this Letter refer to the rapidity ranges |y|<0.9 and 2.5<y<4 and have been obtained by measuring the electron and muon pair decay channels, respectively. The integrated luminosities for the two channels are Linte=1.1 nb−1 and Lintμ=19.9 nb−1, and the corresponding signal statistics are NJ/ψe+e−=59±14 and NJ/ψμ+μ−=1364±53. We present dσJ/ψ/dy for the two rapidity regions under study and, for the forward-y range, d2σJ/ψ/dydpt in the transverse momentum domain 0<pt<8 GeV/c. The results are compared with previously published results at s=7 TeV and with theoretical calculations.
Rapidity and transverse momentum dependence of inclusive J/ψ production in pp collisions at √s=7 TeV
(2011)
The ALICE experiment at the LHC has studied inclusive J/ψ production at central and forward rapidities in pp collisions at √s=7 TeV. In this Letter, we report on the first results obtained detecting the J/ψ through the dilepton decay into e+e− and μ+μ− pairs in the rapidity ranges |y|<0.9 and 2.5<y<4, respectively, and with acceptance down to zero pT. In the dielectron channel the analysis was carried out on a data sample corresponding to an integrated luminosity Lint=5.6 nb−1 and the number of signal events is NJ/ψ=352±32(stat.)±28(syst.); the corresponding figures in the dimuon channel are Lint=15.6 nb−1 and NJ/ψ=1924±77(stat.)±144(syst.). The measured production cross sections are σJ/ψ(|y|<0.9)=10.7±1.0(stat.)±1.6(syst.)−2.3+1.6(syst.pol.)μb and σJ/ψ(2.5<y<4)=6.31±0.25(stat.)±0.76(syst.)−1.96+0.95(syst.pol.)μb. The differential cross sections, in transverse momentum and rapidity, of the J/ψ were also measured.
Heavy flavour decay muon production at forward rapidity in proton–proton collisions at √s=7 TeV
(2012)
The production of muons from heavy flavour decays is measured at forward rapidity in proton–proton collisions at √s=7 TeV collected with the ALICE experiment at the LHC. The analysis is carried out on a data sample corresponding to an integrated luminosity Lint=16.5 nb−1. The transverse momentum and rapidity differential production cross sections of muons from heavy flavour decays are measured in the rapidity range 2.5<y<4, over the transverse momentum range 2<pt<12 GeV/c. The results are compared to predictions based on perturbative QCD calculations.
Inclusive transverse momentum spectra of primary charged particles in Pb–Pb collisions at √sNN=2.76 TeV have been measured by the ALICE Collaboration at the LHC. The data are presented for central and peripheral collisions, corresponding to 0–5% and 70–80% of the hadronic Pb–Pb cross section. The measured charged particle spectra in |η|<0.8 and 0.3<pT<20 GeV/c are compared to the expectation in pp collisions at the same sNN, scaled by the number of underlying nucleon–nucleon collisions. The comparison is expressed in terms of the nuclear modification factor RAA. The result indicates only weak medium effects (RAA≈0.7) in peripheral collisions. In central collisions, RAA reaches a minimum of about 0.14 at pT=6–7 GeV/c and increases significantly at larger pT. The measured suppression of high-pT particles is stronger than that observed at lower collision energies, indicating that a very dense medium is formed in central Pb–Pb collisions at the LHC.
The ALICE experiment has measured the inclusive J/ψ production in Pb-Pb collisions at sNN−−−√=2.76 TeV down to zero transverse momentum in the rapidity range 2.5<y<4. A suppression of the inclusive J/ψ yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0-80% most central collisions, is 0.545±0.032(stat.)±0.083(syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/ψ production from charm quarks in a deconfined partonic phase can describe our data.
The ALICE experiment has measured the inclusive J/psi production in Pb-Pb collisions at sqrt(sNN) = 2.76 TeV down to zero transverse momentum in the rapidity range 2.5 < y < 4. A suppression of the inclusive J/psi yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0%-80% most central collisions, is 0.545+/-0.032(stat)+/-0.083(syst) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/psi production from charm quarks in a deconfined partonic phase can describe our data.
The ALICE experiment has measured the inclusive J/ψ production in Pb-Pb collisions at sNN−−−√=2.76 TeV down to zero transverse momentum in the rapidity range 2.5<y<4. A suppression of the inclusive J/ψ yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0-80% most central collisions, is 0.545±0.032(stat.)±0.083(syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/ψ production from charm quarks in a deconfined partonic phase can describe our data.
The ALICE experiment has measured the inclusive J/psi production in Pb-Pb collisions at sqrt(sNN) = 2.76 TeV down to pt = 0 in the rapidity range 2.5 < y < 4. A suppression of the inclusive J/psi yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0%-80% most central collisions, is 0.545 +/- 0.032 (stat.) +/- 0.084 (syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from lower energy measurements. Models including J/psi production from charm quarks in a deconfined partonic phase can describe our data.
Hintergrund: Ab Frühjahr 2020 kam es zur weltweiten Verbreitung von SARS-CoV‑2 mit der heute als erste Welle der Pandemie bezeichneten Phase ab März 2020. Diese resultierte an vielen Kliniken in Umstrukturierungen und Ressourcenverschiebungen. Ziel unserer Arbeit war die Erfassung der Auswirkungen der Pandemie auf die universitäre Hals-Nasen-Ohren(HNO)-Heilkunde für die Forschung, Lehre und Weiterbildung. Material und Methoden: Die Direktorinnen und Direktoren der 39 Universitäts-HNO-Kliniken in Deutschland wurden mithilfe einer strukturierten Online-Befragung zu den Auswirkungen der Pandemie im Zeitraum von März bis April 2020 auf die Forschung, Lehre und die Weiterbildung befragt. Ergebnisse: Alle 39 Direktorinnen und Direktoren beteiligten sich an der Umfrage. Hiervon gaben 74,4 % (29/39) an, dass es zu einer Verschlechterung ihrer Forschungstätigkeit infolge der Pandemie gekommen sei. Von 61,5 % (24/39) wurde berichtet, dass pandemiebezogene Forschungsaspekte aufgegriffen wurden. Von allen Kliniken wurde eine Einschränkung der Präsenzlehre berichtet und 97,5 % (38/39) führten neue digitale Lehrformate ein. Im Beobachtungszeitraum sahen 74,4 % der Klinikdirektoren die Weiterbildung der Assistenten nicht gefährdet. Schlussfolgerung: Die Ergebnisse geben einen Einblick in die heterogenen Auswirkungen der Pandemie. Die kurzfristige Bearbeitung pandemiebezogener Forschungsthemen und die Einführung innovativer digitaler Konzepte für die studentische Lehre belegt eindrücklich das große innovative Potenzial und die schnelle Reaktionsfähigkeit der HNO-Universitätskliniken, um auch während der Pandemie ihre Aufgaben in der Forschung, Lehre und Weiterbildung bestmöglich zu erfüllen.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.
Rationale: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are important regulators of inflammation. The exact impact of ROS/RNS on cutaneous delayed-type hypersensitivity reaction (DTHR) is controversial. The aim of our study was to identify the dominant sources of ROS/RNS during acute and chronic trinitrochlorobenzene (TNCB)-induced cutaneous DTHR in mice with differently impaired ROS/RNS production.
Methods: TNCB-sensitized wild-type, NADPH oxidase 2 (NOX2)- deficient (gp91phox-/-), myeloperoxidase-deficient (MPO-/-), and inducible nitric oxide synthase-deficient (iNOS-/-) mice were challenged with TNCB on the right ear once to elicit acute DTHR and repetitively up to five times to induce chronic DTHR. We measured ear swelling responses and noninvasively assessed ROS/RNS production in vivo by employing the chemiluminescence optical imaging (OI) probe L-012. Additionally, we conducted extensive ex vivo analyses of inflamed ears focusing on ROS/RNS production and the biochemical and morphological consequences.
Results: The in vivo L-012 OI of acute and chronic DTHR revealed completely abrogated ROS/RNS production in the ears of gp91phox-/- mice, up to 90 % decreased ROS/RNS production in the ears of MPO-/- mice and unaffected ROS/RNS production in the ears of iNOS-/- mice. The DHR flow cytometry analysis of leukocytes derived from the ears with acute DTHR confirmed our in vivo L-012 OI results. Nevertheless, we observed no significant differences in the ear swelling responses among all the experimental groups. The histopathological analysis of the ears of gp91phox-/- mice with acute DTHRs revealed slightly enhanced inflammation. In contrast, we observed a moderately reduced inflammatory immune response in the ears of gp91phox-/- mice with chronic DTHR, while the inflamed ears of MPO-/- mice exhibited the strongest inflammation. Analyses of lipid peroxidation, 8-hydroxy-2'deoxyguanosine levels, redox related metabolites and genomic expression of antioxidant proteins revealed similar oxidative stress in all experimental groups. Furthermore, inflamed ears of wild-type and gp91phox-/- mice displayed neutrophil extracellular trap (NET) formation exclusively in acute but not chronic DTHR.
Conclusions: MPO and NOX2 are the dominant sources of ROS/RNS in acute and chronic DTHR. Nevertheless, depletion of one primary source of ROS/RNS exhibited only marginal but conflicting impact on acute and chronic cutaneous DTHR. Thus, ROS/RNS are not a single entity, and each species has different properties at certain stages of the disease, resulting in different outcomes.
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.
Background: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.
Objective: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.
Methods: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).
Results: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.
Conclusion: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients
Background: Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) is highly heterogeneous. Patients harboring one group of uncommon, recurrent EGFR mutations (G719X, S768I, L861Q) respond to EGFR-TKI. Exon 20 insertions are mostly insensitive to EGFR-TKI but display sensitivity to exon 20 inhibitors. Clinical outcome data of patients with very rare point and compound mutations upon systemic treatments are still sparse to date.
Patients and methods: In this retrospective, multicenter study of the national Network Genomic Medicine (nNGM) in Germany, 856 NSCLC cases with atypical EGFR mutations including co-occurring mutations were reported from 12 centers. Clinical follow-up data after treatment with different EGFR-TKIs, chemotherapy and immune checkpoint inhibitors were available from 260 patients. Response to treatment was analyzed in three major groups: (i) uncommon mutations (G719X, S7681, L861Q and combinations), (ii) exon 20 insertions and (iii) very rare EGFR mutations (very rare single point mutations, compound mutations, exon 18 deletions, exon 19 insertions).
Results: Our study comprises the largest thus far reported real-world cohort of very rare EGFR single point and compound mutations treated with different systemic treatments. We validated higher efficacy of EGFR-TKI in comparison to chemotherapy in group 1 (uncommon), while most exon 20 insertions (group 2) were not EGFR-TKI responsive. In addition, we found TKI sensitivity of very rare point mutations (group 3) and of complex EGFR mutations containing exon 19 deletions or L858R mutations independent of the combination partner. Notably, treatment responses in group 3 (very rare) were highly heterogeneous. Co-occurring TP53 mutations exerted a non-significant trend for a detrimental effect on outcome in EGFR-TKI-treated patients in groups 2 and 3 but not in group 1.
Conclusions: Based on our findings, we propose a novel nNGM classification of atypical EGFR mutations.
Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. BD shows substantial clinical and genetic overlap with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying this etiological overlap remain largely unknown. A recent SCZ genome wide association study (GWAS) by the Psychiatric Genomics Consortium identified 128 independent genome-wide significant single nucleotide polymorphisms (SNPs). The present study investigated whether these SCZ-associated SNPs also contribute to BD development through the performance of association testing in a large BD GWAS dataset (9747 patients, 14278 controls). After re-imputation and correction for sample overlap, 22 of 107 investigated SCZ SNPs showed nominal association with BD. The number of shared SCZ-BD SNPs was significantly higher than expected (p = 1.46x10-8). This provides further evidence that SCZ-associated loci contribute to the development of BD. Two SNPs remained significant after Bonferroni correction. The most strongly associated SNP was located near TRANK1, which is a reported genome-wide significant risk gene for BD. Pathway analyses for all shared SCZ-BD SNPs revealed 25 nominally enriched gene-sets, which showed partial overlap in terms of the underlying genes. The enriched gene-sets included calcium- and glutamate signaling, neuropathic pain signaling in dorsal horn neurons, and calmodulin binding. The present data provide further insights into shared risk loci and disease-associated pathways for BD and SCZ. This may suggest new research directions for the treatment and prevention of these two major psychiatric disorders.
Electroencephalography (EEG) represents a widely established method for assessing altered and typically developing brain function. However, systematic studies on EEG data quality, its correlates, and consequences are scarce. To address this research gap, the current study focused on the percentage of artifact-free segments after standard EEG pre-processing as a data quality index. We analyzed participant-related and methodological influences, and validity by replicating landmark EEG effects. Further, effects of data quality on spectral power analyses beyond participant-related characteristics were explored. EEG data from a multicenter ADHD-cohort (age range 6 to 45 years), and a non-ADHD school-age control group were analyzed (ntotal = 305). Resting-state data during eyes open, and eyes closed conditions, and task-related data during a cued Continuous Performance Task (CPT) were collected. After pre-processing, general linear models, and stepwise regression models were fitted to the data. We found that EEG data quality was strongly related to demographic characteristics, but not to methodological factors. We were able to replicate maturational, task, and ADHD effects reported in the EEG literature, establishing a link with EEG-landmark effects. Furthermore, we showed that poor data quality significantly increases spectral power beyond effects of maturation and symptom severity. Taken together, the current results indicate that with a careful design and systematic quality control, informative large-scale multicenter trials characterizing neurophysiological mechanisms in neurodevelopmental disorders across the lifespan are feasible. Nevertheless, results are restricted to the limitations reported. Future work will clarify predictive value.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Introduction: Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) occurs approximately 1 in 3.500 live births representing the most common malformation of the upper digestive tract. Only half a century ago, EA/TEF was fatal among affected newborns suggesting that the steady birth prevalence might in parts be due to mutational de novo events in genes involved in foregut development.
Methods: To identify mutational de novo events in EA/TEF patients, we surveyed the exome of 30 case-parent trios. Identified and confirmed de novo variants were prioritized using in silico prediction tools. To investigate the embryonic role of genes harboring prioritized de novo variants we performed targeted analysis of mouse transcriptome data of esophageal tissue obtained at the embryonic day (E) E8.5, E12.5, and postnatal.
Results: In total we prioritized 14 novel de novo variants in 14 different genes (APOL2, EEF1D, CHD7, FANCB, GGT6, KIAA0556, NFX1, NPR2, PIGC, SLC5A2, TANC2, TRPS1, UBA3, and ZFHX3) and eight rare de novo variants in eight additional genes (CELSR1, CLP1, GPR133, HPS3, MTA3, PLEC, STAB1, and PPIP5K2). Through personal communication during the project, we identified an additional EA/TEF case-parent trio with a rare de novo variant in ZFHX3. In silico prediction analysis of the identified variants and comparative analysis of mouse transcriptome data of esophageal tissue obtained at E8.5, E12.5, and postnatal prioritized CHD7, TRPS1, and ZFHX3 as EA/TEF candidate genes. Re-sequencing of ZFHX3 in additional 192 EA/TEF patients did not identify further putative EA/TEF-associated variants.
Conclusion: Our study suggests that rare mutational de novo events in genes involved in foregut development contribute to the development of EA/TEF.
Using 9.9 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.15 and 4.30 GeV, we search for the processes e+e−→γX(3872) with X(3872)→π0χc0 and X(3872)→ππχc0. Depending on the fitting model, the statistical significance for X(3872)→π0χc0 ranges from 1.3σ to 2.8σ. We set upper limits (at 90\% C.L.) of B(X(3872)→π0χc0)B(X(3872)→π+π−J/ψ)<3.6, B(X(3872)→π+π−χc0)B(X(3872)→π+π−J/ψ)<0.68, and B(X(3872)→π0π0χc0)B(X(3872)→π+π−J/ψ)<1.7. Combined with the BESIII measurement of X(3872)→π0χc1, we also set an upper limit of B(X(3872)→π0χc0)B(X(3872)→π0χc1)<4.4.
Using 9.9 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.15 and 4.30 GeV, we search for the processes e+e−→γX(3872) with X(3872)→π0χc0 and X(3872)→ππχc0. Depending on the fitting model, the statistical significance for X(3872)→π0χc0 ranges from 1.3σ to 2.8σ. We set upper limits (at 90\% C.L.) of B(X(3872)→π0χc0)B(X(3872)→π+π−J/ψ)<3.6, B(X(3872)→π+π−χc0)B(X(3872)→π+π−J/ψ)<0.68, and B(X(3872)→π0π0χc0)B(X(3872)→π+π−J/ψ)<1.7. Combined with the BESIII measurement of X(3872)→π0χc1, we also set an upper limit of B(X(3872)→π0χc0)B(X(3872)→π0χc1)<4.4.
Using 9.9 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.15 and 4.30 GeV, we search for the processes e+e−→γX(3872) with X(3872)→π0χc0 and X(3872)→ππχc0. Depending on the fitting model, the statistical significance for X(3872)→π0χc0 ranges from 1.3σ to 2.8σ. We set upper limits (at 90\% C.L.) of B(X(3872)→π0χc0)B(X(3872)→π+π−J/ψ)<3.6, B(X(3872)→π+π−χc0)B(X(3872)→π+π−J/ψ)<0.68, and B(X(3872)→π0π0χc0)B(X(3872)→π+π−J/ψ)<1.7. Combined with the BESIII measurement of X(3872)→π0χc1, we also set an upper limit of B(X(3872)→π0χc0)B(X(3872)→π0χc1)<4.4.
We search for the semi-leptonic decays Λ + c → Λπ+π−e+νe and Λ + c → pK0 Sπ−e+νe in a sample of 4.5 fb−1 of e+e− annihilation data collected in the center-of-mass energy region between 4.600 GeV and 4.699 GeV by the BESIII detector at the BEPCII. No significant signals are observed, and the upper limits on the decay branching fractions are set to be B(Λ+c → Λπ+π−e+νe ) < 3.9 × 10−4 and B(Λ + c → pK0Sπ−e+νe ) < 3.3 × 10−4 at the 90% confidence level, respectively.
Using 7.33 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.128 and 4.226~GeV, we observe for the first time the decay D±s→ωπ±η with a statistical significance of 7.6σ. The measured branching fraction of this decay is (0.54±0.12±0.04)%, where the first uncertainty is statistical and the second is systematic.
The decays J/ψ→ηΣ+Σ¯− and ψ(3686)→ηΣ+Σ¯− are observed for the first time, using (10087±44)×106 J/ψ and (448.1±2.9)×106 ψ(3686) events collected with the BESIII detector at the BEPCII collider. We determine the branching fractions of these two decays to be B(J/ψ→ηΣ+Σ¯−)=(6.34±0.21±0.37)×10−5 and B(ψ(3686)→ηΣ+Σ¯−)=(9.59±2.37±0.61)×10−6, where the first uncertainties are statistical and the second are systematic. The ratio of these two branching fractions is determined to be B(ψ(3686)→ηΣ+Σ¯−)B(J/ψ→ηΣ+Σ¯−)=(15.1±3.8)%, which is in agreement with the "12\% rule."
Quantum-correlated 𝐷¯𝐷 pairs collected by the BESIII experiment at the 𝜓(3770) resonance corresponding to an integrated luminosity of 2.93 fb−1 are used to study the 𝐷0→𝐾0𝑆𝜋+𝜋−𝜋0 decay mode. The 𝐶𝑃-even fraction of 𝐷0→𝐾0𝑆𝜋+𝜋−𝜋0 decays is determined to be 0.235±0.010±0.002, where the first uncertainty is statistical and the second is systematic.
Quantum-correlated DD¯ pairs collected by the BESIII experiment at the ψ(3770) resonance, corresponding to an integrated luminosity of 2.93 fb−1, are used to study the D0→K0Sπ+π−π0 decay mode. The CP-even fraction of D0→K0Sπ+π−π0 decays is determined to be 0.235±0.010±0.002, where the first uncertainty is statistical and the second is systematic.
he decay D→K−π+ is studied in a sample of quantum-correlated DD¯ pairs, based on a data set corresponding to an integrated luminosity of 2.93\,fb−1 collected at the ψ(3770) resonance by the BESIII experiment. The asymmetry between CP-odd and CP-even eigenstate decays into K−π+ is determined to be AKπ=0.132±0.011±0.007, where the first uncertainty is statistical and the second is systematic. This measurement is an update of an earlier study exploiting additional tagging modes, including several decay modes involving a K0L meson. The branching fractions of the K0L modes are determined as input to the analysis in a manner that is independent of any strong phase uncertainty. Using the predominantly CP-even tag D→π+π−π0 and the ensemble of CP-odd eigenstate tags, the observable Aπππ0Kπ is measured to be 0.130±0.012±0.008. The two asymmetries are sensitive to rKπDcosδKπD, where rKπD and δKπD are the ratio of amplitudes and phase difference, respectively, between the doubly Cabibbo-suppressed and Cabibbo-favoured decays. In addition, events containing D→K−π+ tagged by D→K0S,Lπ+π− are studied in bins of phase space of the three-body decays. This analysis has sensitivity to both rKπDcosδKπD and rKπDsinδKπD. A fit to AKπ, Aπππ0Kπ and the phase-space distribution of the D→K0S,Lπ+π− tags yields δKπD=(187.5+8.9−9.7+5.4−6.4) degrees, where external constraints are applied for rKπD and other relevant parameters. This is the most precise measurement of δKπD in quantum-correlated DD¯ decays.
The decay D→K−π+ is studied in a sample of quantum-correlated DD¯ pairs, based on a data set corresponding to an integrated luminosity of 2.93\,fb−1 collected at the ψ(3770) resonance by the BESIII experiment. The asymmetry between CP-odd and CP-even eigenstate decays into K−π+ is determined to be AKπ=0.132±0.011±0.007, where the first uncertainty is statistical and the second is systematic. This measurement is an update of an earlier study exploiting additional tagging modes, including several decay modes involving a K0L meson. The branching fractions of the K0L modes are determined as input to the analysis in a manner that is independent of any strong phase uncertainty. Using the predominantly CP-even tag D→π+π−π0 and the ensemble of CP-odd eigenstate tags, the observable Aπππ0Kπ is measured to be 0.130±0.012±0.008. The two asymmetries are sensitive to rKπDcosδKπD, where rKπD and δKπD are the ratio of amplitudes and phase difference, respectively, between the doubly Cabibbo-suppressed and Cabibbo-favoured decays. In addition, events containing D→K−π+ tagged by D→K0S,Lπ+π− are studied in bins of phase space of the three-body decays. This analysis has sensitivity to both rKπDcosδKπD and rKπDsinδKπD. A fit to AKπ, Aπππ0Kπ and the phase-space distribution of the D→K0S,Lπ+π− tags yields δKπD=(187.6+8.9−9.7+5.4−6.4) degrees, where external constraints are applied for rKπD and other relevant parameters. This is the most precise measurement of δKπD in quantum-correlated DD¯ decays.
Using 𝑒+𝑒− collision data corresponding to an integrated luminosity of 7.33 fb−1 recorded by the BESIII detector at center-of-mass energies between 4.128 and 4.226 GeV, we present an analysis of the decay 𝐷+𝑠→𝜋+𝜋−𝑒+𝜈𝑒, where the 𝐷+𝑠 is produced via the process 𝑒+𝑒−→𝐷*±𝑠𝐷∓𝑠. We observe the 𝑓0(980) in the 𝜋+𝜋− system and the branching fraction of the decay 𝐷+𝑠→𝑓0(980)𝑒+𝜈𝑒 with 𝑓0(980)→𝜋+𝜋− measured to be (1.72±0.13stat±0.10syst)×10−3, where the uncertainties are statistical and systematic, respectively. The dynamics of the 𝐷+𝑠→𝑓0(980)𝑒+𝜈𝑒 decay are studied with the simple pole parametrization of the hadronic form factor and the Flatté formula describing the 𝑓0(980) in the differential decay rate, and the product of the form factor 𝑓𝑓0+(0) and the 𝑐→𝑠 Cabibbo-Kobayashi-Maskawa matrix element |𝑉𝑐𝑠| is determined for the first time to be 𝑓𝑓0+(0)|𝑉𝑐𝑠|=0.504±0.017stat±0.035syst. Furthermore, the decay 𝐷+
𝑠→𝑓0(500)𝑒+𝜈𝑒 is searched for the first time but no signal is found. The upper limit on the branching fraction of 𝐷+𝑠→𝑓0(500)𝑒+𝜈𝑒, 𝑓0(500)→𝜋+𝜋− decay is set to be 3.3×10−4 at 90% confidence level.
A narrow structure in the pΛ¯ system near the mass threshold, named as X(2085), is observed in the process e+e−→pK−Λ¯ with a statistical significance greater than 20σ. Its spin and parity are determined for the first time to be JP=1+ in an amplitude analysis, with statistical significance greater than 5σ over other quantum numbers. The pole positions of X(2085) are measured to be Mpole=(2086±4±6)~MeV and Γpole=(56±5±16) MeV, where the first uncertainties are statistical and the second ones are systematic. The analysis is based on the study of the process e+e−→pK−Λ¯ and uses the data samples collected with the BESIII detector at the center-of-mass energies s√=4.008, 4.178, 4.226, 4.258, 4.416, and 4.682 GeV with a total integrated luminosity of 8.35 fb−1.
Based on a sample of 448.1×106 ψ(3686) events collected with the BESIII detector, a study of ψ(3686)→ΛΛ¯π0 and ψ(3686)→ΛΛ¯η is performed. Evidence of the isospin-violating decay ψ(3686)→ΛΛ¯π0 is found for the first time with a statistical significance of 3.7σ, the branching fraction B(ψ(3686)→ΛΛ¯π0) is measured to be (1.42±0.39±0.59)×10−6, and its corresponding upper limit is determined to be 2.47×10−6 at 90\% confidence level. A partial wave analysis of ψ(3686)→ΛΛ¯η shows that the peak around Λη invariant mass threshold favors a Λ∗ resonance with mass and width in agreement with the Λ(1670). The branching fraction of the ψ(3686)→ΛΛ¯η is measured to be (2.34±0.18±0.52)×10−5. The first uncertainties are statistical and the second are systematic.
Based on e+e− collision data corresponding to an integrated luminosity of 4.5 fb−1 collected at the center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII, the absolute branching fraction of the inclusive decay Λ+c→n+X, where X refers to any possible final state particles, is measured. The absolute branching fraction is determined to be B(Λ+c→n+X)=(32.4±0.7±1.5)%, where the first uncertainty is statistical and the second systematic. Assuming CP symmetry, the measurement indicates that about one-fourth of Λ+c (Λ¯−c) decay modes with a neutron (an anti-neutron) in the final state have not been observed.
Based on e+e− collision data corresponding to an integrated luminosity of 4.5 fb−1 collected at the center-of-mass energies between 4.600 and 4.699 Gev with the BESIII detector at BEPCII, the absolute branching fraction of the inclusive decay Λ¯−c→n¯+X, where X refers to any possible final state particles, is measured. The absolute branching fraction is determined to be B(Λ¯−c→n¯+X)=(33.5±0.7±1.2)%, where the first uncertainty is statistical and the second systematic. Neglecting the effect of CP violation, the measurement indicates that about one-fourth of Λ+c decay modes with a neutron in the final state have not been observed.
First study of reaction Ξ⁰n → Ξ⁻ p using Ξ⁰-nucleus scattering at an electron-positron collider
(2023)
Using ð1.0087 0.0044Þ × 1010 J=ψ events collected with the BESIII detector at the BEPCII storage ring, the process Ξ0n → Ξ−p is studied, where the Ξ0 baryon is produced in the process J=ψ → Ξ0Ξ¯ 0 and the neutron is a component of the 9 Be, 12C, and 197Au nuclei in the beam pipe. A clear signal is observed with a statistical significance of 7.1σ. The cross section of the reaction Ξ0 þ 9 Be → Ξ− þ p þ 8 Be is determined to be σðΞ0 þ 9 Be → Ξ− þ p þ 8 BeÞ¼ð22.1 5.3stat 4.5sysÞ mb at the Ξ0 momentum of 0.818 GeV=c, where the first uncertainty is statistical and the second is systematic. No significant H-dibaryon signal is observed in the Ξ−p final state. This is the first study of hyperon-nucleon interactions in electron-positron collisions and opens up a new direction for such research.
Based on (448.1±2.9)×106 ψ(3686) events collected with the BESIII detector operating at the BEPCII collider, the decay ψ(3686)→ϕK0SK0S is observed for the first time. Taking the interference between ψ(3686) decay and continuum production into account, the branching fraction of this decay is measured to be B(ψ(3686)→ϕK0SK0S) = (3.53 ± 0.20 ± 0.21)×10−5, where the first uncertainty is statistical and the second is systematic. Combining with the world average value for B(J/ψ→ϕK0SK0S), the ratio B(ψ(3686)→ϕK0SK0S)/B(J/ψ→ϕK0SK0S) is determined to be (6.0±1.6)%, which is suppressed relative to the 12% rule.
Using initial-state radiation events from a total integrated luminosity of 11.957 fb−1 of 𝑒+𝑒− collision data collected at center-of-mass energies between 3.773 and 4.258 GeV with the BESIII detector at BEPCII, the cross section for the process 𝑒+𝑒−→Λ¯Λ is measured in 16 Λ¯Λ invariant mass intervals from the production threshold up to 3.00 GeV/𝑐2. The results are consistent with previous results from BABAR and BESIII, but with better precision and with narrower Λ¯Λ invariant mass intervals than BABAR.
The radiative hyperon decay Λ→𝑛𝛾 is studied using (10087±44)×106 𝐽/𝜓 events collected with the BESIII detector operating at BEPCII. The absolute branching fraction of the decay Λ→𝑛𝛾 is determined to be (0.832±0.038stat±0.054syst)×10−3, which is a factor of 2.1 lower and 5.6 standard deviations different than the previous measurement. By analyzing the joint angular distribution of the decay products, the first determination of the decay asymmetry 𝛼𝛾 is reported with a value of −0.16±0.10stat±0.05syst.
Cross sections for the process e+e−→K0SK0SJ/ψ at center-of-mass energies from 4.128 to 4.950 GeV are measured using data samples with a total integrated luminosity of 21.2 fb−1 collected by the BESIII detector operating at the BEPCII storage ring. The Y(4230) state is observed in the energy dependence of the e+e−→K0SK0SJ/ψ cross section for the first time with a statistical significance of 26.0σ. In addition, an enhancement around 4.710 GeV, called the Y(4710), is seen with a statistical significance of 4.2σ. There is no clear structure around 4.484 GeV. Using a fit with a coherent sum of three Breit-Wigner functions, we determine the mass and width of the Y(4230) state to be 4226.9±6.6±21.9 MeV/c2 and 71.7±16.2±31.4 MeV, respectively, and the mass and width of the Y(4710) state to be 4704.0±52.3±69.5 MeV/c2 and 183.2±114.0±90.8 MeV, respectively, where the first uncertainties are statistical and the second are systematic. In addition, the average Born cross section ratio of e+e−→K0SK0SJ/ψ to e+e−→K+K−J/ψ is measured to be 0.388+0.035−0.028±0.016, or 0.426+0.038−0.031±0.018 if three-body phase space is considered.
Based on 7.33 fb−1 of e+e− collision data taken at center-of-mass energies between 4.128 and 4.226 GeV with the BESIII detector, we measure the branching fraction of D∗+s→D+sπ0 relative to that of D∗+s→D+sγ to be (6.16±0.43±0.19)%. The first uncertainty is statistical and the second one is systematic. By using the world average value of the branching fraction of D∗+s→D+se+e−, we determine the branching fractions of D∗+s→D+sγ and D∗+s→D+sπ0 to be (93.57±0.44±0.19)% and (5.76±0.44±0.19)%, respectively.
A precision measurement of the matrix elements for η→π+π−π0 and η→π0π0π0 decays is performed using a sample of (10087±44)×106 J/ψ decays collected with the BESIII detector. The decay J/ψ→γη is used to select clean samples of 631,686 η→π+π−π0 decays and 272,322 η→π0π0π0 decays. The matrix elements for both channels are in reasonable agreement with previous measurements. The non-zero gX2Y term for the decay mode η→π+π−π0 is confirmed, as reported by the KLOE Collaboration, while the other higher-order terms are found to be insignificant. Dalitz plot asymmetries in the η→π+π−π0 decay are also explored and are found to be consistent with charge conjugation invariance. In addition, a cusp effect is investigated in the η→π0π0π0 decay, and no obvious structure around the π+π− mass threshold is observed.
Cross sections for the process e+e−→K0SK0SJ/ψ at center-of-mass energies from 4.128 to 4.950 GeV are measured using data samples with a total integrated luminosity of 21.2 fb−1 collected by the BESIII detector operating at the BEPCII storage ring. The Y(4230) state is observed in the energy dependence of the e+e−→K0SK0SJ/ψ cross section for the first time with a statistical significance of 26.0σ. In addition, an enhancement around 4.710 GeV, called the Y(4710), is seen with a statistical significance of 4.2σ. There is no clear structure around 4.484 GeV. Using a fit with a coherent sum of three Breit-Wigner functions, we determine the mass and width of the Y(4230) state to be 4226.9±6.6±21.9 MeV/c2 and 71.7±16.2±31.4 MeV, respectively, and the mass and width of the Y(4710) state to be 4704.0±52.3±69.5 MeV/c2 and 183.2±114.0±90.8 MeV, respectively, where the first uncertainties are statistical and the second are systematic. In addition, the average Born cross section ratio of e+e−→K0SK0SJ/ψ to e+e−→K+K−J/ψ is measured to be 0.388+0.035−0.028±0.016, or 0.426+0.038−0.031±0.018 if three-body phase space is considered.
Using 7.33 fb−1 of e+e− collision data taken with the BESIII detector at the BEPCII collider, we report the first experimental study of the purely leptonic decay D∗+s→e+νe. A signal for the decay D∗+s→e+νe is observed with a statistical significance of 2.9σ. The branching fraction of D∗+s→e+νe is measured to be (2.1+1.2−0.9stat.±0.2syst.)×10−5, corresponding to an upper limit of 4.0×10−5 at the 90\% confidence level. Taking the total width of the D∗+s~((0.070±0.028) keV) predicted by lattice quantum chromodynamics as input, the decay constant of the D∗+s is determined to be fD∗+s=(213.6+61.0−45.8stat.±43.9syst.) MeV, corresponding to an upper limit of 353.8 MeV at the 90\% confidence level.
Using 7.33 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.128 and 4.226~GeV, we observe for the first time the decay D±s→ωπ±η with a statistical significance of 7.6σ. The measured branching fraction of this decay is (0.54±0.12±0.04)%, where the first uncertainty is statistical and the second is systematic.
Measurements of the electric and magnetic form factors of the neutron for timelike momentum transfer
(2023)
We present the first measurements of the electric and magnetic form factors of the neutron in the time-like (positive q2) region as function of four-momentum transfer. We explored the differential cross sections of the reaction e+e−→n¯n with data collected with the BESIII detector at the BEPCII accelerator, corresponding to an integrated luminosity of 354.6 pb−1 in total at twelve center-of-mass energies between s√=2.0−2.95 GeV. A relative uncertainty of 18% and 12% for the electric and magnetic form factors, respectively, is achieved at s√=2.3935 GeV. Our results are comparable in accuracy to those from electron scattering in the comparable space-like (negative q2) region of four-momentum transfer. The electromagnetic form factor ratio Rem≡|GE|/|GM| is within the uncertainties close to unity. We compare our result on |GE| and |GM| to recent model predictions, and the measurements in the space-like region to test the analyticity of electromagnetic form factors.
Using e+e− annihilation data corresponding to an integrated luminosity of 2.93 fb−1 taken at a center-of-mass energy of 3.773 GeV with the BESIII detector, we report the first measurements of the branching fractions of the inclusive decays D0→π+π+π−X and D+→π+π+π−X, where pions from K0S decays have been excluded from the π+π+π− system and X denotes any possible particle combination. The branching fractions of D0(D+)→π+π+π−X are determined to be B(D0→π+π+π−X)=(17.60±0.11±0.22)% and B(D+→π+π+π−X)=(15.25±0.09±0.18)%, where the first uncertainties are statistical and the second systematic.
Using a data sample of e+e− collision data corresponding to an integrated luminosity of 19 fb−1 collected with the BESIII detector at the BEPCII collider, we search for the production of deuterons and antideuterons via e+e−→ppπ−d¯+c.c. for the first time at center-of-mass energies between 4.13 and 4.70 GeV. No significant signal is observed and the upper limit of the e+e−→ppπ−d¯+c.c. cross section is determined to be from 9.0 to 145 fb depending on the center-of-mass energy at the 90% confidence level.